{
    "info": {
        "nct_id": "NCT06770764",
        "official_title": "A Phase 1/1b, Multicenter, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Pharmacodynamics, and Pharmacokinetics of ODC-IL2 Administered Via Intravenous Infusion in Adult Patients With Advanced or Metastatic Solid Tumors",
        "inclusion_criteria": "Each patient must meet all the following criteria to participate in the study:\n\n1. Histologically or cytologically confirmed advanced or metastatic solid tumors, for which no other standard treatment is available or appropriate, or for which the Trutino Biosciences Protocol #: TRT-ODC-IL2-001 Version: 1.0 Date: 20 September 2024 standard of care is refused by the patient due to tolerability or the Investigator believes the patient will not tolerate standard-of-care therapy\n2. Advanced or metastatic tumors measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n4. Life expectancy of at least 3 months;\n5. Age ≥ 18 years;\n6. Signed, written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent\n7. Acceptable liver function:\n\n   * Bilirubin ≤ 1.5 times upper limit of normal (ULN) or ≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia).\n   * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)\n8. Acceptable renal function:\n\n   • Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation.\n9. Acceptable hematologic status:\n\n   * Absolute neutrophil count ≥ 1500 cells/mm3\n   * Platelet count ≥ 75,000 (plt/mm3)\n   * Hemoglobin ≥ 9 g/dL\n10. A negative serum pregnancy test (if a woman of childbearing potential);\n11. Women of childbearing potential (WOCBP) and men with WOCBP partners must agree to use adequate contraception (hormonal method of birth control; intrauterine devices or abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of study drug. Should a female trial participant or a female partner of a male trial participant become pregnant or suspect she is pregnant during the study, the Investigator must be informed immediately.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG)\n2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of > 470 msec\n3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n4. Known active brain metastases; patients with previously treated, clinically stable, radiologically stable brain metastases (without evidence of progression in 4 weeks) and without the requirement for treatment with corticosteroids in prior 3 weeks may be considered for enrollment after discussion with the Medical Monitor\n5. History of prior organ transplant\n6. Conditions requiring systemic treatment with corticosteroids or any other form of immunosuppressive therapy within 7 days prior to start of study drug.\n7. History of autoimmune diseases requiring systemic immunosuppressive therapy in the last 2 years\n8. Pregnant or nursing women.\n9. Treatment with radiation therapy, major surgery, chemotherapy, or investigational therapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). Radiation for palliation of pain is allowed within 1 week prior to study entry, but the lesion should not be selected as a target lesion for RECIST analysis.\n10. Unwillingness or inability to comply with procedures required in this protocol\n11. Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type 1 (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV)\n\n    * Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable\n    * Active infection with HIV and CD4+ T-cell count <350/μL. Patients not on established anti-retroviral therapy for at least 4 weeks and having a detectable HIV viral load\n12. Serious uncontrolled nonmalignant disease (e.g., renal failure, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor\n13. Prior treatment with an IL-2 targeted treatment, unless given as a part of a tumor infiltrating lymphocyte treatment combination;\n14. Known sensitivity to IL-2 or any of the excipients in ODC-IL2;\n15. Active treatment with heparin or heparin-related therapies, unless the patient can be transitioned to a non-heparin treatment for the clinical condition with an adequate washout prior to enrollment in the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Hemoglobin ≥ 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Acceptable renal function:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Advanced or metastatic tumors measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;",
            "criterions": [
                {
                    "exact_snippets": "Advanced or metastatic tumors",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
                    "criterion": "tumor measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "measurable per RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation.",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation.",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin ≤ 1.5 times upper limit of normal (ULN) or ≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia).",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 times upper limit of normal (ULN)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia)",
                    "criterion": "bilirubin level in patients with Gilbert's Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "times institutional ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Age ≥ 18 years;",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Life expectancy of at least 3 months;",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Acceptable liver function:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable liver function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Women of childbearing potential (WOCBP) and men with WOCBP partners must agree to use adequate contraception (hormonal method of birth control; intrauterine devices or abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of study drug. Should a female trial participant or a female partner of a male trial participant become pregnant or suspect she is pregnant during the study, the Investigator must be informed immediately.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) and men with WOCBP partners must agree to use adequate contraception (hormonal method of birth control; intrauterine devices or abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of study drug.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "hormonal method of birth control",
                                "intrauterine devices",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "prior to study entry, for the duration of study participation and for 4 months after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "women of childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men with WOCBP partners",
                    "criterion": "male participant with WOCBP partner",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 1500 cells/mm3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1500 cells/mm3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Acceptable hematologic status:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable hematologic status",
                    "criterion": "hematologic status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 75,000 (plt/mm3)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 75,000 (plt/mm3)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "plt/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Signed, written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent",
            "criterions": [
                {
                    "exact_snippets": "Signed, written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "IRB/EC-approved",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. A negative serum pregnancy test (if a woman of childbearing potential);",
            "criterions": [
                {
                    "exact_snippets": "A negative serum pregnancy test (if a woman of childbearing potential)",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "if a woman of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed advanced or metastatic solid tumors, for which no other standard treatment is available or appropriate, or for which the Trutino Biosciences Protocol #: TRT-ODC-IL2-001 Version: 1.0 Date: 20 September 2024 standard of care is refused by the patient due to tolerability or the Investigator believes the patient will not tolerate standard-of-care therapy",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed advanced or metastatic solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no other standard treatment is available or appropriate",
                    "criterion": "standard treatment availability or appropriateness",
                    "requirements": [
                        {
                            "requirement_type": "availability or appropriateness",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "standard of care is refused by the patient due to tolerability",
                    "criterion": "standard of care refusal",
                    "requirements": [
                        {
                            "requirement_type": "refusal by patient",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "reason for refusal",
                            "expected_value": "tolerability"
                        }
                    ]
                },
                {
                    "exact_snippets": "the Investigator believes the patient will not tolerate standard-of-care therapy",
                    "criterion": "investigator assessment of standard-of-care tolerability",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment of tolerability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)",
                    "criterion": "alkaline phosphatase level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "11. Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type 1 (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV)",
            "criterions": [
                {
                    "exact_snippets": "Known active infection with human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active infection with ... human T-cell leukemia virus, type 1 (HTLV-1)",
                    "criterion": "human T-cell leukemia virus, type 1 (HTLV-1) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active infection with ... hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active infection with ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History of prior organ transplant",
            "criterions": [
                {
                    "exact_snippets": "History of prior organ transplant",
                    "criterion": "prior organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial ... requiring systemic therapy",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... viral ... requiring systemic therapy",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... fungal ... requiring systemic therapy",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Treatment with radiation therapy, major surgery, chemotherapy, or investigational therapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). Radiation for palliation of pain is allowed within 1 week prior to study entry, but the lesion should not be selected as a target lesion for RECIST analysis.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with radiation therapy, major surgery, chemotherapy, or investigational therapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)",
                    "criterion": "recent cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "radiation therapy",
                                "major surgery",
                                "chemotherapy",
                                "investigational therapy"
                            ]
                        },
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time since nitrosoureas or mitomycin C",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiation for palliation of pain is allowed within 1 week prior to study entry",
                    "criterion": "palliative radiation for pain",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the lesion should not be selected as a target lesion for RECIST analysis",
                    "criterion": "lesion treated with palliative radiation",
                    "requirements": [
                        {
                            "requirement_type": "selection as RECIST target lesion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Active treatment with heparin or heparin-related therapies, unless the patient can be transitioned to a non-heparin treatment for the clinical condition with an adequate washout prior to enrollment in the study.",
            "criterions": [
                {
                    "exact_snippets": "Active treatment with heparin or heparin-related therapies",
                    "criterion": "heparin or heparin-related therapy use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the patient can be transitioned to a non-heparin treatment for the clinical condition with an adequate washout prior to enrollment",
                    "criterion": "transition to non-heparin treatment with adequate washout",
                    "requirements": [
                        {
                            "requirement_type": "transition to non-heparin treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequate washout prior to enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Known sensitivity to IL-2 or any of the excipients in ODC-IL2;",
            "criterions": [
                {
                    "exact_snippets": "Known sensitivity to IL-2",
                    "criterion": "sensitivity to IL-2",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known sensitivity to ... any of the excipients in ODC-IL2",
                    "criterion": "sensitivity to excipients in ODC-IL2",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Conditions requiring systemic treatment with corticosteroids or any other form of immunosuppressive therapy within 7 days prior to start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Conditions requiring systemic treatment with corticosteroids ... within 7 days prior to start of study drug.",
                    "criterion": "systemic corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to start of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Conditions requiring ... any other form of immunosuppressive therapy within 7 days prior to start of study drug.",
                    "criterion": "systemic immunosuppressive therapy (other than corticosteroids)",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to start of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of > 470 msec",
            "criterions": [
                {
                    "exact_snippets": "corrected QT interval (using Fridericia's correction formula) (QTcF) of > 470 msec",
                    "criterion": "corrected QT interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Serious uncontrolled nonmalignant disease (e.g., renal failure, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor",
            "criterions": [
                {
                    "exact_snippets": "Serious uncontrolled nonmalignant disease (e.g., renal failure, liver failure, or other conditions)",
                    "criterion": "nonmalignant disease",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "renal failure",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "liver failure",
                    "criterion": "liver failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Unwillingness or inability to comply with procedures required in this protocol",
            "criterions": [
                {
                    "exact_snippets": "Unwillingness ... to comply with procedures required in this protocol",
                    "criterion": "willingness to comply with protocol procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to comply with procedures required in this protocol",
                    "criterion": "ability to comply with protocol procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known active brain metastases; patients with previously treated, clinically stable, radiologically stable brain metastases (without evidence of progression in 4 weeks) and without the requirement for treatment with corticosteroids in prior 3 weeks may be considered for enrollment after discussion with the Medical Monitor",
            "criterions": [
                {
                    "exact_snippets": "Known active brain metastases",
                    "criterion": "active brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with previously treated, clinically stable, radiologically stable brain metastases (without evidence of progression in 4 weeks)",
                    "criterion": "brain metastases (previously treated, clinically and radiologically stable, no progression in 4 weeks)",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "clinical_stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "radiological_stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression_free_interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without the requirement for treatment with corticosteroids in prior 3 weeks",
                    "criterion": "requirement for corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG)",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Class III or IV",
                    "criterion": "New York Heart Association (NYHA) class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of ischemia on electrocardiogram (ECG)",
                    "criterion": "ischemia on electrocardiogram (ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection with HIV and CD4+ T-cell count <350/μL. Patients not on established anti-retroviral therapy for at least 4 weeks and having a detectable HIV viral load",
            "criterions": [
                {
                    "exact_snippets": "Active infection with HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "CD4+ T-cell count <350/μL",
                    "criterion": "CD4+ T-cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 350,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients not on established anti-retroviral therapy for at least 4 weeks",
                    "criterion": "anti-retroviral therapy duration",
                    "requirements": [
                        {
                            "requirement_type": "duration_on_therapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "having a detectable HIV viral load",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Pregnant or nursing women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable",
            "criterions": [
                {
                    "exact_snippets": "history of hepatitis B or C",
                    "criterion": "history of hepatitis B or C",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HBV DNA ... undetectable",
                    "criterion": "HBV DNA",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV RNA ... undetectable",
                    "criterion": "HCV RNA",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of autoimmune diseases requiring systemic immunosuppressive therapy in the last 2 years",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune diseases",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring systemic immunosuppressive therapy",
                    "criterion": "systemic immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the last 2 years",
                    "criterion": "time since systemic immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Prior treatment with an IL-2 targeted treatment, unless given as a part of a tumor infiltrating lymphocyte treatment combination;",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with an IL-2 targeted treatment, unless given as a part of a tumor infiltrating lymphocyte treatment combination",
                    "criterion": "prior IL-2 targeted treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "allowed if given as part of a tumor infiltrating lymphocyte treatment combination"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Each patient must meet all the following criteria to participate in the study:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}